ArticleFrontiers in pharmacology2025
Pharmacovigilance practice on off-label high-dose of vancomycin in severely ill children.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the safety of off-label high-dose vancomycin use in severely ill children and explore strategies to control risks. Methods: A case of acute kidney injury caused by off-label high-dose vancomycin (exceeding 40 mg/kg/day) in the Pediatric Intensive Care Unit (PICU) was analyzed. A retrospective case-control review of vancomycin treatment in 39 PICU patients from January to June 2020 were conducted. Findings: Among the 39 patients, 20 (51.3%) received off-label high-dose vancomycin dosing, and only 53.8% (21/39) underwent blood concentration testing. Five patients (25%; 5/20) in the off-label use group experienced vancomycin-associated adverse reactions, including three cases of severe ones. Based on risk factor analysis, we implemented improvement measures such as increasing the monitoring of vancomycin trough serum concentration, providing individualized drug regimens, enhancing training, and formally documenting off-label drug use. After implementing these measures from July 2020 to December 2022, a total of 86 children in the PICU were treated with vancomycin, and no cases of vancomycin-associated acute kidney injury was observed. The monitoring rate of vancomycin blood concentration increased to 88.4% (76/86). Implications: There is a risk of renal function damage when using high dosage of vancomycin in severely ill children, and healthcare providers should pay special attention to this in clinical medication safety practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.